Neurokinin-1 Receptor Antagonist Orvepitant for PTSD
This study is completed in the United States. It is testing Neurokinin-1 Receptor Antagonist Orvepitant for PTSD.
PTSDDrugFrom 18 Years to 64 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether orvepitant may be useful for adults experiencing ptsd.
What would participation involve?
Participants may receive orvepitant, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United States.
Who is it mainly for?
This study appears to be mainly for adults with ptsd.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: November 2, 2009
Recruitment status
Completed
Enrollment listed in the registry
132
Sponsor
GlaxoSmithKline
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug, OTHER
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 64 Years
Official registry ID
NCT01000493
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study Evaluating the Efficacy and Safety of the Neurokinin-1 Receptor Antagonist Orvepitant (GW823296) in Post Traumatic Stress Disorder (PTSD)
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT01000493. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
United States · 26 sites
GSK Investigational Site
Birmingham, Alabama
Site status: Not listed — confirm with the team
GSK Investigational Site
Scottsdale, Arizona
Site status: Not listed — confirm with the team
GSK Investigational Site
Beverly Hills, California
Site status: Not listed — confirm with the team
GSK Investigational Site
Torrance, California
Site status: Not listed — confirm with the team
GSK Investigational Site
Jacksonville, Florida
Site status: Not listed — confirm with the team
GSK Investigational Site
Orlando, Florida
Site status: Not listed — confirm with the team
GSK Investigational Site
Marietta, Georgia
Site status: Not listed — confirm with the team
GSK Investigational Site
Park Ridge, Illinois
Site status: Not listed — confirm with the team
GSK Investigational Site
Indianapolis, Indiana
Site status: Not listed — confirm with the team
GSK Investigational Site
Glen Burnie, Maryland
Site status: Not listed — confirm with the team
GSK Investigational Site
Weymouth, Massachusetts
Site status: Not listed — confirm with the team
GSK Investigational Site
Willingboro, New Jersey
Site status: Not listed — confirm with the team
GSK Investigational Site
The Bronx, New York
Site status: Not listed — confirm with the team
GSK Investigational Site
Raleigh, North Carolina
Site status: Not listed — confirm with the team
GSK Investigational Site
Dayton, Ohio
Site status: Not listed — confirm with the team
GSK Investigational Site
Garfield Heights, Ohio
Site status: Not listed — confirm with the team
GSK Investigational Site
Tulsa, Oklahoma
Site status: Not listed — confirm with the team
GSK Investigational Site
Charleston, South Carolina
Site status: Not listed — confirm with the team
GSK Investigational Site
Memphis, Tennessee
Site status: Not listed — confirm with the team
GSK Investigational Site
Austin, Texas
Site status: Not listed — confirm with the team
GSK Investigational Site
Dallas, Texas
Site status: Not listed — confirm with the team
GSK Investigational Site
Houston, Texas
Site status: Not listed — confirm with the team
GSK Investigational Site
Salt Lake City, Utah
Site status: Not listed — confirm with the team
GSK Investigational Site
Seattle, Washington
Site status: Not listed — confirm with the team
GSK Investigational Site
Brown Deer, Wisconsin
Site status: Not listed — confirm with the team
GSK Investigational Site
Middleton, Wisconsin
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
Based on the public registry summary, this study is trying to understand: This is a 12-week, randomized, multicenter, double-blind, placebo controlled, fixed-dose parallel group study to assess the efficacy and safety of orvepitant (60 mg/day) versus placebo in subjects with a diagnosis of noncombat-related Posttraumatic Stress Disorder (PTSD), whose. The study team can confirm the exact objective and what it means for you.
Does this study involve a medication?
This appears to be a medication / drug study involving orvepitant, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with ptsd; age range: From 18 Years to 64 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
Will I need to change, stop, or stabilize my current treatment?
The public registry appears to mention rules about current treatment, stability, stopping treatment, or dose changes. Do not change your treatment for a study without medical guidance. Ask the study team and your clinician what is required, what is not allowed, and how safety is monitored.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by GlaxoSmithKline, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
